Stock Analysis
ZOETIS INC.ZTS
P/E 12.54×· 5Y range 10.94–59.46×· bottom 7% of history
Sector: Healthcare · Industry: Medical Devices
AnalystsBuy24 analystsP/E 12.5× sits at the 7th percentile of its 5.086926762491444-year history.
Cash covers 18% of debt · Q2 2026.
PMP Verdict
Strong business, attractive price
Strengths
- Profitability100
- Quality94
Risks
- Growth48
High-quality business at an attractive price.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 4.1 — safe-zone balance sheet
- ✓ROE 83.1% — efficient capital deployment
- ✓Interest coverage 14.9× — debt well covered
- ✓P/E 12.5× at bottom 7% of 5-year history
What's happening with ZTS
Profile
Strong profitability, moat, earnings quality, valuation and financial health; growth lags behind.
How is each axis scored?
- Valuation85/100 · Strong
- P/E vs own history (7th pct)25/25
- FCF yield (7.2%)20/25
- P/S (3.5x)20/25
- EV/EBIT (11.7x)20/25
- Growth48/100 · Weak
- Revenue CAGR (5.0%)12/25
- Net income CAGR (7.0%)12/25
- EPS CAGR 5Y (9.0%)12/25
- Fwd implied growth (10.8%)12/25
- Profitability100/100 · Strong
- ROIC (25.6%)25/25
- ROE (83.1%)25/25
- Net margin (27.5%)25/25
- Operating margin (36.6%)25/25
- Financial Health75/100 · Strong
- Altman Z (4.11)25/25
- Current ratio (3.08)25/25
- Interest coverage (14.9x)25/25
- Net cash / debt (D/A 50%)0/25
- Quality94/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.65)25/25
- FCF conversion (90%)22/25
- Margin stability (σ 4.6%)25/25
- Moat100/100 · Strong
- ROIC >12% years (10/10 yrs)25/25
- Median gross margin (69.4%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 16.3%)25/25
About ZOETIS INC.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. Show more
The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Headquarters: PARSIPPANY, NJ · Employees: 14,500 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
85AP/E (TTM)12.6xA
Grade A: CheapPrice / TTM EPS (own statements) — vs own 5Y history: 10.9x–59.5x · 7th pct
P/FCF13.7xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield7.2%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 1.4%–8.3% · 94th pct
P/S (TTM)3.47xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 3.0x–15.5x · 7th pct
EV/EBIT11.7xA
Grade A: CheapEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 10.4x–50.4x · 6th pct
EV/Sales4.2xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E11.4xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio10.50xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio2.09C
Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield2.73%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio34.0%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
100A+ROIC25.6%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE83.1%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA17.2%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin27.5%A
Grade A: HighNet Income / Revenue
Operating Margin36.6%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin71.5%A
Grade A: PremiumGross Profit / Revenue
FCF Margin24.9%A
Grade A: HighFCF / Revenue
True FCF Margin23.9%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
48D+Revenue CAGR5.0%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR7.0%C
Grade C: OkCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)9.0%C
Grade C: OkCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth10.8%B
Grade B: LowAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-13.5%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income3.6%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.0%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score4.11A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio3.08xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio1.83xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage14.9xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment3.2yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT2.2xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity2.94xD
Grade D: HighDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.18xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
94A+Piotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.65A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion90.4%A
Grade A: StrongFCF / Net Income
Margin Stability4.6%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue5.5%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.63xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Esch Kevin Filed | Esch Kevin | Grant / award | +360 | |
Driscoll Rimma Filed | Driscoll Rimma | Grant / award | +278 | |
FULLER JULIE Filed | FULLER JULIE | Grant / award | +368 | |
Sarbaugh Keith Filed | Sarbaugh Keith | Grant / award | +303 | |
Ferran Astorga Jeannette Filed | Ferran Astorga Jeannette | Grant / award | +53 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Nayak Abhay U Filed | Nayak Abhay U | Grant / award | +321 | |
Lagano Roxanne Filed | Lagano Roxanne | Grant / award | +368 | |
PECK KRISTIN C Filed | PECK KRISTIN C | Grant / award | +720 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
100A+ROIC >12% Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)69.4%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor16.3%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$6.33
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$4.04
Cash & short-term investments per share (Finnhub)
Book Value / Share$7.60
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$9.26B
Total debt obligations (short + long term)
Cash & Equiv.$1.68B
Cash and short-term investments
Net Debt$7.58B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$3.15B
Shareholders' equity (book value)
Asset / Liability1.26xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$33.06B
Current Market Capitalization
Beta0.71B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: ZOETIS INC. (ZTS)
ZTS is up 1.22% at the last close. ZOETIS INC. meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 4.11 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.65 suggests a low likelihood of earnings manipulation. ZOETIS INC. converts about 25% of revenue into free cash flow — strong cash generation.
- Takes ~3.2 years to repay net debt from free cash flow.
- At a valuation score of 85/100, ZTS trades near the cheapest end of its own historical range (P/E 12.6).
- Return on equity of 83.1% is well above the market average.
- The stock currently yields 2.7% in dividends.
See how ZTS ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ZTS moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 78.68 | +4.50% | 2.77 |
| Oct 15 | After-hours | 78.87 | +4.76% | 2.93 |
| Oct 5 | Regular | 71.40 | +2.45% | 2.30 |
| Oct 5 | After-hours | 71.20 | +2.17% | 2.07 |
| Sep 22 | Regular | 73.27 | +2.71% | 2.27 |
Frequently Asked Questions about ZTS
What is the current ZOETIS INC. (ZTS) stock price?
ZTS is trading at $79.38 at the last market close, up 1.22% on the session. PreMarketPrice tracks ZTS pre-market, intraday and after-hours prices.
Is ZTS stock a buy right now?
PreMarketPrice's quantitative model rates ZOETIS INC.'s financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ZTS stock overvalued?
ZOETIS INC. trades at a trailing P/E of 12.6 and our valuation score rates it 85/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does ZOETIS INC. report earnings?
No confirmed earnings date is currently scheduled for ZTS. The Earnings section lists recent reports and updates as dates are announced.
What sector does ZOETIS INC. operate in?
ZOETIS INC. operates in the Healthcare sector, within the Medical Devices industry. The Related Stocks section lists sector peers for comparison.
What does ZOETIS INC. do?
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals.
About ZOETIS INC. (ZTS) Stock
ZOETIS INC. (ZTS) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry. As of the latest update, ZOETIS INC. is trading at $79.38, up 1.22% on the day with a market capitalization of $33.1 billion. The financial health score for ZTS is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ZTS stock.
ZTS Stock Analysis & Key Metrics
On PreMarketPrice, you can track ZOETIS INC. (ZTS) across multiple dimensions:
- Pre-market price & movement: Real-time ZTS stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ZTS with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for ZOETIS INC. across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ZTS.
- Sector peers: Compare ZTS against 6 other healthcare stocks on key financial metrics.
Is ZTS a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate ZOETIS INC. (ZTS) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.ZOETIS INC. (ZTS) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.